TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00112502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
Study: NCT01367574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC MNTX
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC MNTX
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC MNTX
Description: Dose 3
Study: NCT03634787

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan Day 5-7
Description: Computed Tomography on Day 5-7 according to a clinical protocol.
Study: NCT02670044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally as per schedule in Arm description.
Study: NCT03649724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
Study: NCT02670044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally as per schedule in Arm description.
Study: NCT01988142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.
Study: NCT02423863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab
Study: NCT03649724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eligard 22.5Mg Suspension for Injection
Description: Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
Study: NCT01925404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free physical activity classes
Description: 100 hours of free activity classes will be provided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free physical activity classes
Description: 100 hours of free activity classes will be provided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent User
Description: Participants can become eligible for prizes by visiting the park more frequently

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequent User
Description: Participants can become eligible for prizes by visiting the park more frequently
Study: NCT04602637

Intervention type: OTHER
Intervention: Training load
Description: Monitoring training load during covid

Intervention type: OTHER
Intervention: Training load
Description: Monitoring training load during covid

Intervention type: OTHER
Intervention: Training load
Description: Monitoring training load during covid
Study: NCT01938911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon-Spray
Description: Intranasal oxytocin (24 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of syntocinon
Description: Intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of syntocinon
Description: Intranasal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of syntocinon
Description: Intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of syntocinon
Description: Intranasal administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Social support from the best friend

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Social support from the best friend

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Social support from the best friend

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Social support from the best friend
Study: NCT01496092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keto Acid
Description: 12 tablets per day
Study: NCT01571206

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
Study: NCT03503721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BipolEP
Description: the prostate will be transurethrally enucleated using a bipolar current

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolarTURP
Description: the prostate will transurethrally resected using a bipolar current
Study: NCT00749320

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Spin Labeling Magnetic Resonance Imaging
Description: ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
Study: NCT01932827

Intervention type: BEHAVIORAL
Intervention: Mock Package Questionnaire
Description: Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
Study: NCT00877695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entre Culturas: Navigating Culture, Identity, and HIV Risk
Description: A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entre Culturas: Navigating Culture, Identity, and HIV Risk
Description: A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entre Culturas: Navigating Culture, Identity, and HIV Risk
Description: A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
Study: NCT04566419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC - Airvo 2
Description: high flow nasal cannulae delivering 60 l/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: oxygen delivered by Venturi mask
Study: NCT03407742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPAS Youth
Description: 9-week parenting intervention
Study: NCT03691064

Intervention type: DRUG
Intervention: LUTATHERA
Description: Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
Study: NCT03662542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab Dose 1 will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab Dose 1 will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab Dose 2 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab Dose 2 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab Dose 1
Description: Golimumab Dose 1 will be administered as SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab Dose 1
Description: Golimumab Dose 1 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab Dose 2
Description: Golimumab Dose 2 will be administered as SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab Dose 2
Description: Golimumab Dose 2 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT03296527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa
Description: GONAL-F dose was fixed for the first 5 stimulation days.
Study: NCT03662542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT00006294

Intervention type: DRUG
Intervention: Chlorthalidone
Description: participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study

Intervention type: DRUG
Intervention: Lisinopril
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study

Intervention type: DRUG
Intervention: Amlodipine
Description: participant's drug dose will be titrated from 10mg to 40mg over the course of the study

Intervention type: DRUG
Intervention: Doxazosin
Description: participant's drug dose will be titrated from 2mg to 8mg over the course of the study
Study: NCT01816893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic hyperinsulinemic clamp

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Euglycemic hyperinsulinemic clamp
Study: NCT01904604

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Viaskin® Patch
Description: Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose DBV712 Viaskin® Patch
Description: 100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose DBV712 Viaskin® Patch
Description: 250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
Study: NCT04031833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT2203
Description: Encochleated amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT2203
Description: Encochleated amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAT2203
Description: Encochleated amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Intravenous amphotericin B
Study: NCT03302585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Standard of Care Vitamin D3
Description: 50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
Study: NCT01145768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: 4 mg tablet, oral, BID, group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: TBD tablet, oral, BID, groups 2-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00621881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod
Description: 750 mg bid
Study: NCT03071172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Choriogonadotropin alfa Solution for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study: NCT03145896

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
Study: NCT04409093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nail bed repair with eponychial sent
Description: The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nail bed repair without eponychial stent
Description: The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
Study: NCT01890668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility...) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Osteopathic manipulative Treatment
Description: Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months
Study: NCT02732431

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Symptom
Description: Questionnaires, skin allergy test, overnight polysomnography
Study: NCT04599036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARK
Description: EMG controlled arm orthosis
Study: NCT01620762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose every 4 weeks
Study: NCT00588094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Description: ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue.